Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
21.43
-1.26 (-5.55%)
At close: Aug 8, 2025, 4:00 PM
22.08
+0.65 (3.03%)
After-hours: Aug 8, 2025, 6:49 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Reimbursement | 138.35M | Log In | Log In | Log In | Log In | Upgrade |
Reimbursement Growth | -1.06% | Log In | Log In | Log In | Log In | Upgrade |
Milestone | 138.90M | Log In | Log In | Log In | Log In | Upgrade |
Milestone Growth | - | Log In | Log In | Log In | Log In | Upgrade |
License | 277.81K | Log In | Log In | Log In | Log In | Upgrade |
Other | 242.11M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 158.67% | Log In | Log In | Log In | Log In | Upgrade |
DARZALEX Royalties | 1.93B | Log In | Log In | Log In | Log In | Upgrade |
DARZALEX Royalties Growth | 23.73% | Log In | Log In | Log In | Log In | Upgrade |
Kesimpta Royalties | 308.65M | Log In | Log In | Log In | Log In | Upgrade |
Kesimpta Royalties Growth | 42.83% | Log In | Log In | Log In | Log In | Upgrade |
TEPEZZA Royalties | 102.37M | Log In | Log In | Log In | Log In | Upgrade |
TEPEZZA Royalties Growth | 0.71% | Log In | Log In | Log In | Log In | Upgrade |
Other Product Royalties | 65.42M | Log In | Log In | Log In | Log In | Upgrade |
Other Product Royalties Growth | 75.58% | Log In | Log In | Log In | Log In | Upgrade |
Collaboration | 60.15M | Log In | Log In | Log In | Log In | Upgrade |
Collaboration Growth | 32.49% | Log In | Log In | Log In | Log In | Upgrade |
Net Product Sales | 242.11M | Log In | Log In | Log In | Log In | Upgrade |
Net Product Sales Growth | 157.61% | Log In | Log In | Log In | Log In | Upgrade |
J&J | 2.00B | Log In | Log In | Log In | Log In | Upgrade |
J&J Growth | 22.42% | Log In | Log In | Log In | Log In | Upgrade |
Novartis | 391.99M | Log In | Log In | Log In | Log In | Upgrade |
Novartis Growth | 75.94% | Log In | Log In | Log In | Log In | Upgrade |
BioNTech | 120.71M | Log In | Log In | Log In | Log In | Upgrade |
BioNTech Growth | -7.14% | Log In | Log In | Log In | Log In | Upgrade |
Pfizer | 74.04M | Log In | Log In | Log In | Log In | Upgrade |
Pfizer Growth | 34.51% | Log In | Log In | Log In | Log In | Upgrade |
Other Collaboration Partner | 277.81K | Log In | Log In | Log In | Log In | Upgrade |
Other Collaboration Partner Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Roche | 102.93M | Log In | Log In | Log In | Log In | Upgrade |
Roche Growth | 1.27% | Log In | Log In | Log In | Log In | Upgrade |
AbbVie | 54.73M | Log In | Log In | Log In | Log In | Upgrade |
AbbVie Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Denmark | 2.75B | Log In | Log In | Log In | Log In | Upgrade |
Denmark Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States | 125.29M | Log In | Log In | Log In | Log In | Upgrade |
Japan | 116.82M | Log In | Log In | Log In | Log In | Upgrade |